MedElevator Войти в исследования
← Поиск публикаций
NPJ precision oncology · 2026

Dual pancreatic carcinomas: clonally related or independent primaries?

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Schoenfeld Joshua D, Ravichandran Vignesh, Tarcan Zeynep, Sahin-Ozkan Hulya, Richards Allison L, Bilani Nadeem, Chou Joanne F, O'Connor Catherine A, McManamon David, Varghese Anna M, Keane Fergus, D'Angelica Michael I, Jarnagin William R, Drebin Jeffrey, Reidy-Lagunes Diane, Wei Alice C, Chalasani Sree B, Balogun Fiyinfolu, Park Wungki, Yu Kenneth H, Soares Kevin, Donoghue Mark T A, Iacobuzio-Donahue Christine, Stadler Zsofia K, Capanu Marinela, Basturk Olca, O'Reilly Eileen M

Аннотация

Dual pancreatic cancers, either synchronous or metachronous in presentation, are a rare occurrence. It remains unclear if these lesions are clonally related or independently occurring primary malignancies. Herein we present a cohort (N = 22) with dual pancreatic ductal adenocarcinoma (PDAC) tumors to resolve previously conflicting reports and interrogate the underlying biological and clinical characteristics of this patient population. Next-generation sequencing of paired lesions (N = 10) revealed that while most dual PDAC are clonally related, independently occurring lesions do occur, irrespective of the interval between lesions. Integrated clinical, genomic, and histopathological analyses revealed a high frequency of lymph node-negative, intraductal papillary mucinous neoplasm (IPMN)-associated cancers, KRAS and/or SMAD4 wild-type tumors, and classical subtype by immunohistochemistry, all collectively associated with more favorable outcomes. Acknowledging the highly selected nature of this cohort, isolated intrapancreatic metastases demonstrate a more indolent biology and these patients may benefit from personalized management approaches beyond traditional paradigms.